BACKGROUND:Hyaluronan with special linear macromolecular structure and rheologic property has good biocompatibility and becomes a signal matter of the cel surface, which possesses a promising application potential in tissue-engineering field. OBJECTIVE:To review the research progress in medical hyaluronan composites. METHODS:Related literatures concerning preparation, safety evaluation and clinical trials of hyaluronan composites were extensively reviewed and comprehensively analyzed in the three folowing aspects: cartilage scaffold, cornea scaffold and submucous bulking agent. RESULTS AND CONCLUSION:The hyaluronan composite has a potential use in cartilage scaffold and cornea scaffold as its suitable porosity and pore size, biomimetic three-dimensional microstructure, excelent physical and chemical property and biological property. The hyaluronan composite as a bulking agent has been applied clinicaly, and results from some clinical trials have shown that the composite used as bulking agent has the problems about low efficacy and complications, which need to do further improvement. More researches are needed in product design, evaluation of performance and safety for expending and optimizing the clinical applications of the hyaluronan composite.

According to the discipline construction, Nursing and Health Management Department of Nanfang Hospital of Southern Medical University conducted exploration in its nursing work from the points of health management center nursing care, nursing staff management, physical examination process optimiza-tion, service concept and etiquette and other aspects, and at the same time conducted satisfaction survey. Survey and statistical results showed that the customer satisfaction reached more than 90%. It indicated that great achievements were made in the health management nursing work, and a complete set of health man-agement nursing model was formed which adapted to the change of medical model and the development of social economy.

Idiopathic hypogonadotropic hypogonadism (IHH) is characterized by delayed or absent puberty and lowered sexual function as a result of impaired pulsatile gonadotropin-realeasing hormone (GnRH) secretion.Identification of TAC3/TACR3 mutations as the culprits of IHH revealed that neurokinin B (NKB) signaling pathway was involved in the regulation of pulsatile GnRH secretion.This review focuses on the involvement of NKB signaling in pulsatile GnRH release,the discovery of TAC3/TACR3 mutations and the phenotypes,and treatment of patients who carry TAC3 or/and TACR3 mutations.

Objective To evaluate the efficacy of oral etopside (VP16) and oral cyclophosphamide (CPM) combination in the treatment of hormone-refractory prostate cancer (HRPC). Methods Between June 2000 and July 2003,9 patients with HRPC were treated with oral etopside (50 mg/d) and oral cyclophosphamide (100 mg/d) for 21 days with every 28 days as a cycle.Inclusion criteria were previous complete androgen blockade,anti-androgen (flutamide) withdrawal evaluation,and clinical or biochemical disease progression.The therapy was continued until there was evidence of disease progression or the patients could not tolerate the adverse effects of the medications. Results All the 9 patients had a mean follow-up of 7.5 months.PSA levels decreased by at least 50%,from pre-treatment of (90.5?43.6)ng/ml to post-treatment of (24.8?22.2)ng/ml,in 4 patients. The mean duration of response was 6.8 months (range,2-15 months).An objective response was obtained in 2 patients (1 of CR and 1 of PR).Toxic and adverse effects were minimal. Conclusions The combination of oral VP16 and CPM may be an efficacious and well-tolerated regimen in patients with HRPC.

50% for more than 1 month as effective,and the efficacy for soft tissue metastases were classified as complete,partial remission,stabilization and progression.Results All patients were followed up for 6-24 months(mean,12 months) with the evaluation of efficacy and toxicity.PSA levels decreased by at least 50% in 6 of 12 cases(50%);it decreased from(63.9?47.3)ng/ml before treatment to(14.4?8.8)ng/ml after treatment,with a mean duration of response being 7.5 months(range,5-12 months).Partial remission of soft tissue metastases was obtained in 2 cases;the metastatic lesions were reduced from 4.0 cm?5.0 cm,(3.0cm?)(3.5) cm to 2.0 cm?2.0 cm,1.0 cm?1.5 cm,respectively,by the treatment,with response duration being 3 and 8 months,respectively.Toxicities were minimal with leukopenia at grade Ⅰ in 1 case,anemia at grade Ⅰ in 1,baldness at grade Ⅰ in 1,nausea at grade Ⅰ in 2 and impaired liver function at grade Ⅱ in 1.Conclusions The combination of oral estramustine phosphate and oral etoposide may be an effective and well-tolerated regimen in patients with HRPC.

ObjectiveTo investigate the clinical efficacy and safety of solifenacin for female overactive bladder (OAB) who failed in toherodine treatment. MethodsFrom Jan 2010 to Oct 2010,48 cases of female OAB were treated with 5 mg/d solifenacin for 4 weeks after the failure of tolterodine treatment.The improvement of the perception of bladder condition as well as the mean numbers of day-time micturition,urgency episodes,urge incontinence episode per day,nocturia and pads usage were used as objective indexes for the evaluation of therapeutic effect. ResultsAfter 4-week solifenacin treatment,the mean numbers of day-time micturition,urgency episodes,urge incontinence episode per day,nocturia and pads usage were respectively decreased from the baselines ( 8.7 ± 1.5),(3.4 ± 2.1 ),( 2.4 ± 1.8 ),(2.1 ± 1.8 ) and (2.2 ±1.6) to be (7.2 ±2.5),(2.0 ±1.8),(1.5 ±1.2),(1.2 ±0.8) and (1.4 ±0.8).The perception of bladder condition was improved in 42 cases.The withdrawal from the treatment was seen in 3 cases due to headache and dry mouth.No severe adverse event was found in the rest 45 patients. Conclusion Solifenacin might be an effective and safe alternative agent in the treatment of female OAB who failed in tolterodine treatment.

Objective For preventing the recurrence of superficial transitional cell carcinoma of bladder. Methods Recombinant interferon-alpha and mitomycin C have been used combindly in cl inical study.42 patients were divided into two groups: recombinant interferon-a lpha plus mitomycin group and mitomycin C group.The protocol of chemoimmunoprop hylaxis include 6 weekly and 6 two weekly instillation of 3?10 7 IU recombinan t interferon-alpha plus 40mg mitomycin C in 40ml normal saline via catheter.Che moimmunotherapy was given once monthly for at least two years. Resul ts Follow-up(from 6 to 30 months with a median of 18 months)consist ed of cystoscopy and cytology with cold cup biopsies carried out every 3 months for 2 years. Recurrence after instillation of recombinant interferon-alpha plus mitomycin C was observed in only 2 (10%). Recombinant interferon-alpha plus mi tomycin C yielded better effect ive rate(P

Purpose:To improve the surgical technique in the treatment of renal pelvic and ureteral malignancy.Methods:From May. 1998 to December. 2000 intravesical ureterectomy has been carried out for 9 cases of renal pelvic malignancy . the distal ureter was intussuscepted into the bladder by traction of a ureteral catheter that had been attached to the cephalad end of the ureter after the kidney was removed. Patients have been followed up for 6 to 30 months with a mean of 18.6 months.Results:No surgical complication has been observed. On cystoscopy, no tumor occurrence has been found at the site of the removed ureteral orifice and other part of the bladder.Conclusions:The surgical technique is characterized by good results,few complication and simplicity.

[Summary] Patients with infertility and non-obese polycystic ovary syndrome ( PCOS) were treated with continuous subcutaneous pulse infusion of GnRH. After the treatment, a 32-year old female had regular menstrual cramps. Dominant follicle occurred after 2 months of treatment. The patient was pregnant and now has a healthy baby boy. It shows that the pulse infusion of GnRH could induce spontaneous ovulation and natural fertilization of the patients with non-obese PCOS.

OBJECTIVE To study the causes of recurrence and treatment methods in patients with recurrent sinonasal melanoma. METHODS From 1993 to 2003, a retrospective analysis of consecutive 11 cases with recurrent sinonasal melanoma was conducted. RESULTS Four out of the 11 cases with recurrent sinonasal melanoma were caused by misdiagnosis, while the other 7 cases recurred after operation with pathological diagnosis. Among the 7 cases, 5 were found recurrences after operation alone, and the other 2 after the operation and radiation therapy. The recurrence lesions located in nasal and paranasal sinus in 7 cases, in orbit, skull base, soft and hard palate in 1 case, in parotid gland and skin in 1 case. In face, orbit and extended skull base in 1 case. Cervical lymph node recurrence developed in 1 patient. The time of first relapse was 10 months after therapy. The 1-, 2-and 3-year survival rates after reoperation were 72.7 %, 18.2 % and 9.1 % respectively. CONCLUSION The reasonable treatment and decrease the misdignosis are the main measures to improve the cure rate of recurrent sinonasal melanoma.